Back to Journals » HIV/AIDS - Research and Palliative Care » Volume 12

Immunological Response During HAART and Determinants of Current CD4+ T-Cell Count Among HIV/AIDS Patients Attending University of Gondar Referral Hospital, Northwest Ethiopia

Authors Manaye GA, Abateneh DD, Kebede KM, Belay AS

Received 2 April 2020

Accepted for publication 12 July 2020

Published 31 July 2020 Volume 2020:12 Pages 295—306

DOI https://doi.org/10.2147/HIV.S255751

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Bassel Sawaya


Gizachew Ayele Manaye,1 Dejene Derseh Abateneh,1,2 Kindie Mitiku Kebede,1 Alemayehu Sayih Belay1

1Mizan Tepi University, College of Health Sciences, Mizan Tefri, Ethiopia; 2Kotebe Metropolitan University, Menelik II College of Medicine and Health Sciences, Addis Ababa, Ethiopia

Correspondence: Dejene Derseh Abateneh
Kotebe Metropolitan University, Menelik II College of Medicine and Health Sciences Department of Medical Laboratory Sciences, P.O. Box: 3268, Addis Ababa, Ethiopia
Tel +251920514158
Email dejenieh@gmail.com

Purpose: After the initiation of highly active antiretroviral therapy (HAART), successful HAART is characterized by an increase in the CD4+ count. Several factors affect the CD4+ T-cell count. This study aimed to assess the immunological response during HAART and determinants of the current CD4+ T-cell count among HIV/AIDS patients on HAART.
Patients and Methods: A hospital-based cross-sectional study was conducted from February 1 to April 1, 2017. A total of 423 HIV/AIDS patients on HAART were enrolled using simple random sampling. Descriptive statistics, and bivariate and multiple regression analyses were conducted. Variables with p-value < 0.2 in the bivariate analysis were entered in the multiple regression models. p-Values < 0.05 and 95% confidence intervals were used to identify determinants of the current CD4+ T-cell count.
Results: The mean CD4+ T-cell count gradually increased until 8 years on HAART but declined thereafter. An increased current CD4+ T-cell count was observed among patients with an initial regimen of pediatric d4T-3TC-NVP [β=185.5, 95% CI (8.8, 362.2)] (p=0.040), with increased baseline CD4+ T-cell count [β=0.468, 95% CI (0.342, 0.594)] (p< 0.0001), and with long duration on HAART [β=18.0, 95% CI (9.9, 26.1)] (p< 0.0001), whereas a decreased level of current CD4+ T-cell count was observed among males [β=− 72.7, 95% CI (− 114.5, – 30.9)]) (p< 0.0001) and those with poor baseline adherence [β=− 108.9, 95% CI (− 210.9, − 7.0)] (p=0.036) and viral load > 1000 copies [β=− 189.2, 95% CI (− 243.5, − 134.9)] (p< 0.0001).
Conclusion: The trend in immunological response was not increased linearly throughout the HAART duration. Sex, type of initial regimen, baseline adherence, baseline CD4+ count, viral load, and duration on HAART were independent determinants of current CD4+ count. These determinants could be addressed by regular monitoring of HIV patients on HAART, and special attention should be paid to male patients.

Keywords: immunological responses, trends, current CD4+ count, HIV/AIDS, HAART

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]